(Total Views: 828)
Posted On: 07/02/2020 6:09:17 PM
Post# of 154006
Re: Bored Lawyer #40700
Bored Lawyer,
Thanks. this are very important news !!!
I saw it coming. Commented on this in a larger post few weeks back, phase 2 was not good and they only continued with 400Mg and their clinical improvement was only 59% vs 41%. Also, the 200mg dose produced more deaths than placebo.
This is a big blow for the advocates of IL-6, for Regeneron and Sanofi AND for the FDA that was taking them by the hand with an adaptive trial. They latter narrowed the trial for only "critical" patients and only with 400mg dosage.
However, I was nervous because ANY show of effectiveness would have been heralded and approved by FDA.
I am sorry for the patients, however this makes a HUGE dent in the interleukin-6 (IL-6) receptor antibody theory … which indirectly favors CYDY to a very large extent.
Remember that the Montefiore patients of Leronlimab had also reduced levels of IL-6 from day 0 to 14 (p=0.0371) approaching almost normal levels (p=0.3431 vs healthy controls). I am sure that at day 21 and onwards the IL-6 levels would had been statistically normal.
So, these news can be read as" another moa hits the dust" … IL-6 has been taunted to be THE "other" human monoclonal antibody drug used as an anti-inflammatory in severely active rheumatoid arthritis with potential to treat COVID-19.
Thanks. this are very important news !!!
I saw it coming. Commented on this in a larger post few weeks back, phase 2 was not good and they only continued with 400Mg and their clinical improvement was only 59% vs 41%. Also, the 200mg dose produced more deaths than placebo.
This is a big blow for the advocates of IL-6, for Regeneron and Sanofi AND for the FDA that was taking them by the hand with an adaptive trial. They latter narrowed the trial for only "critical" patients and only with 400mg dosage.
However, I was nervous because ANY show of effectiveness would have been heralded and approved by FDA.
I am sorry for the patients, however this makes a HUGE dent in the interleukin-6 (IL-6) receptor antibody theory … which indirectly favors CYDY to a very large extent.
Remember that the Montefiore patients of Leronlimab had also reduced levels of IL-6 from day 0 to 14 (p=0.0371) approaching almost normal levels (p=0.3431 vs healthy controls). I am sure that at day 21 and onwards the IL-6 levels would had been statistically normal.
So, these news can be read as" another moa hits the dust" … IL-6 has been taunted to be THE "other" human monoclonal antibody drug used as an anti-inflammatory in severely active rheumatoid arthritis with potential to treat COVID-19.
(12)
(0)
